ライフサイエンスコーパス: suprachoroidal

1 0.001) and 25-fold (p = 0.001) higher after suprachoroidal (2744+/-1111 ng/ml) injection when compar

2 itis, compared with 20mg subtenon injection, suprachoroidal 2mg TA demonstrated much better efficacy

3 Suprachoroidal AAV8 vector injection provides a noninvas

4 acetonide (TACA) in porcine plasma following suprachoroidal administration, which is necessary to est

5 To mask both groups, sham suprachoroidal and intravitreal injections were utilized

6 ce from 18 studies on the use of periocular, suprachoroidal, and intravitreal triamcinolone acetonide

7 tinal site using a novel delivery system and suprachoroidal approach for most participants; however,

8 In addition, suprachoroidal bevacizumab tissue levels declined rapidl

9 To evaluate choroidal and suprachoroidal changes following suprachoroidal injectio

10 Suprachoroidal clearance of Gd-DTPA followed first-order

11 Of 198 patients with NIU, 134 received suprachoroidal CLS-TA (proprietary formulation of a tria

12 seline, the SCS expanded significantly after suprachoroidal CLS-TA injection (16.2 mum to 27.8 mum at

13 aocular corticosteroid injection or implant, suprachoroidal corticosteroid injection, or a combinatio

14 istributed more to the inner retina, whereas suprachoroidal delivery occurred primarily at the choroi

15 31, 2024, focusing on studies investigating suprachoroidal delivery of anti-VEGF therapy.

16 dentified that were relevant to the topic of suprachoroidal delivery of anti-VEGF therapy.

17 omising results thus far have been seen with suprachoroidal delivery of VEGF-targeting therapies in c

18 Notably, suprachoroidal delivery results in higher choroidal drug

19 patients were catheterized with the Oxulumis suprachoroidal delivery system on two separate occasions

20 l molecules should be considered to optimize suprachoroidal delivery.

21 Suprachoroidal Drug Delivery has emerged in recent years

22 posterior suprachoroidal TA led to a visible suprachoroidal drug deposit and prolonged visual improve

23 bility measurements or after incubation with suprachoroidal fluid by measuring the amount of (35)SO(4

24 era obtained immediately after extraction of suprachoroidal fluid for permeability measurements or af

25 id suggested that all inhibitory activity in suprachoroidal fluid fractions specific to recovering ey

26 al glycosaminoglycan synthesis compared with suprachoroidal fluid from control eyes (-54%; P < 0.01;

27 Suprachoroidal fluid isolated from recovering chick eyes

28 was associated with the objective finding of suprachoroidal fluid on OCT-EDI (P = .003), and the freq

29 correlation with the presence and amount of suprachoroidal fluid on OCT-EDI (vasculitis, 0.45 [P < .

30 The presence of suprachoroidal fluid on OCT-EDI appears to correlate wit

31 Preliminary characterization of suprachoroidal fluid suggested that all inhibitory activ

32 in leakage from choroidal blood vessels into suprachoroidal fluid using Evans blue.

33 Suprachoroidal fluid was subjected to size fractionation

34 as been made and compares viral and nonviral suprachoroidal gene delivery for the treatment of retina

35 Suprachoroidal gene therapy is an emerging biotechnology

36 These data indicate that nonviral suprachoroidal gene therapy with optimized polymer, expr

37 delivery to choroid-retina was in the order: suprachoroidal > intravitreal >posterior subconjunctival

38 2 vitrectomy procedures, 39 cases of delayed suprachoroidal hemorrhage (0.8%) were identified.

39 g posterior retinal tear (n = 1) and limited suprachoroidal hemorrhage (n = 1).

40 phthisis after retinal detachment (n=4), and suprachoroidal hemorrhage (n=2).

41 elevated intraocular pressure (P = .88), or suprachoroidal hemorrhage (P = .26).

42 he presentation, management, and outcomes of suprachoroidal hemorrhage (SCH).

43 There was only one case with suprachoroidal hemorrhage during IOL exchange.

44 Risk factors for development of suprachoroidal hemorrhage during pars plana vitrectomy i

45 In eyes with suprachoroidal hemorrhage during pars plana vitrectomy,

46 he vitrectomy were identified as the delayed suprachoroidal hemorrhage group; all other eyes that und

47 nificant risk factors for developing delayed suprachoroidal hemorrhage included advancing age (odds r

48 Suprachoroidal hemorrhage is a potentially devastating c

49 Suprachoroidal hemorrhage is an uncommon but serious com

50 The prognosis is more favorable if the suprachoroidal hemorrhage is localized and does not exte

51 In most cases, intraoperative drainage of suprachoroidal hemorrhage is not associated with a bette

52 Delayed suprachoroidal hemorrhage occurs in 0.8% of vitrectomize

53 Suprachoroidal hemorrhage was more common with increasin

54 owed that the stronger predictors of delayed suprachoroidal hemorrhage were emesis postoperatively (P

55 All eyes that developed delayed suprachoroidal hemorrhage within 48 hours of the end of

56 r, hypotony maculopathy, choroidal effusion, suprachoroidal hemorrhage) in this subgroup of eyes that

57 stoperative adverse events (endophthalmitis, suprachoroidal hemorrhage, retinal detachment) following

58 s-return to operating room, endophthalmitis, suprachoroidal hemorrhage, retinal detachment, retinal t

59 itis, endophthalmitis, hypotony maculopathy, suprachoroidal hemorrhage, retinal detachment, stromal n

60 trectomy in the same period, without delayed suprachoroidal hemorrhage, were considered the control g

61 t anterior chamber, choroidal effusions, and suprachoroidal hemorrhage.

62 i, focal depigmentation, and the presence of suprachoroidal hyporeflective space.

63 howed much less vitreous inflammation in the suprachoroidal injection group (p<0.0001).

64 ompared with other ocular injection methods, suprachoroidal injection has demonstrated wide biodistri

65 Suprachoroidal injection is an emerging technique for dr

66 e, we show in a human-sized minipig eye that suprachoroidal injection of 50 mul of NPs containing 19.

67 port a novel gene therapy delivery approach, suprachoroidal injection of AAV8 vectors, which is less

68 Two weeks after suprachoroidal injection of AAV8.GFP in rats, GFP fluore

69 urred in nonhuman primate and pig eyes after suprachoroidal injection of AAV8.GFP.

70 In terms of viral vectors, suprachoroidal injection of an adeno-associated virus 8

71 Suprachoroidal injection of CLS-TA does not alter choroi

72 ham procedure, demonstrating the efficacy of suprachoroidal injection of CLS-TA for the treatment of

73 sion (TANZANITE) study who received either a suprachoroidal injection of CLS-TA with an intravitreal

74 he current study was designed to compare the suprachoroidal injection of different drug formulations

75 It seems that a 50muL suprachoroidal injection of TA was well tolerated in rab

76 an AAV8 vector expressing an anti-VEGF Fab, suprachoroidal injection of the same dose of RGX-314 res

77 dy evaluated the efficacy of combined use of suprachoroidal injection of triamcinolone acetonide (SCT

78 gard of the potential efficacy and safety of suprachoroidal injection of Triamcinolone Acetonide (TA)

79 oroidal and suprachoroidal changes following suprachoroidal injection of triamcinolone acetonide inje

80 dema due to RVO, enrolled in the prospective Suprachoroidal Injection of Triamcinolone Acetonide with

81 sure (AUC(0-360min)) to choroid-retina after suprachoroidal injection was 6-fold (p = 0.001) and 2-fo

82 umab or a viscoelastic-enhanced microcannula suprachoroidal injection was performed with either 1.25

83 terature, a promising approach is the use of suprachoroidal injection with viral and nonviral gene de

84 After 50muL TA (Kenalog-40) suprachoroidal injection, 4-5 animals at 7 time points w

85 Suprachoroidal injection, a new approach for drug delive

86 After suprachoroidal injection, IOP had an acute elevation, hi

87 Following a 50muL suprachoroidal injection, peak TA concentration in the a

88 ficantly smaller IOP elevation than after TA suprachoroidal injection.

89 very platforms such as bioerodible implants, suprachoroidal injections (CLS-AX/axitinib), micropartic

90 ) was observed immediately after dosing with suprachoroidal injections and at 10 and 27.5 minutes, re

91 Suprachoroidal injections are feasible in a rat model.

92 of 200 mul and markedly reduced after three suprachoroidal injections at different locations around

93 After 2 suprachoroidal injections of AAV8.GFP, GFP fluorescence

94 Suprachoroidal injections of fluorescein and fluorescent

95 Suprachoroidal injections resulted in the highest bioava

96 s, including intravitreal hydrogel implants, suprachoroidal injections, subcutaneous delivery systems

97 r ocular drug delivery, specifically through suprachoroidal injections.

98 ministration (e.g., periocular transscleral, suprachoroidal, intravitreal) on the ocular distribution

99 te factors responsible for visibility of the suprachoroidal layer (SCL) and suprachoroidal space (SCS

100 s a hyporeflective band corresponding to the suprachoroidal layer (SCL).

101 ontrast, intrascleral infusions expanded the suprachoroidal layer and delivered Gd-DTPA to the poster

102 but fetal eyes, SM cells were present in the suprachoroidal layer, forming a reticulum of flattened l

103 nd clinical outcomes from the use of a novel suprachoroidal microcatheter to treat post-surgical chro

104 Suprachoroidal microcatheterization for posterior delive

105 Suprachoroidal MIGS create a cyclodialysis and increase

106 Twelve months after suprachoroidal MIGS, mean ECD loss was 282 cells/mm(2) (

107 Suprachoroidal nonviral gene therapy with biodegradable

108 inal trabeculotomy], surgeries that increase suprachoroidal outflow (Cypass microstent and iStent Sup

109 at post-surgical chronic ME by the posterior suprachoroidal placement of a triamcinolone acetonide (T

110 In a rabbit model, suprachoroidal polypropylene and gold shunts allow acces

111 aF was compared in Sprague Dawley rats after suprachoroidal, posterior subconjunctival, or intravitre

112 afety, and efficacy for gene therapy via the suprachoroidal route.

113 g administration by various routes including suprachoroidal route.

114 Suprachoroidal (SC) delivery facilitates targeting, comp

115 lyzed the long-term safety of the EYEMATE-SC suprachoroidal sensor system (Implandata).

116 a sulcus-based sensor and 21 patients with a suprachoroidal sensor).

117 Injection of suprachoroidal sodium hyaluronate, 1%, in the region of

118 Drug delivery to the suprachoroidal space (SCS(R)) has become a clinical real

119 rapy showed a trend toward thickening of the suprachoroidal space (SCS) compared with monotherapy alo

120 slow release of Bev after injection into the suprachoroidal space (SCS) of the eye using a microneedl

121 bility of the suprachoroidal layer (SCL) and suprachoroidal space (SCS).

122 om 20 nm to 10 mum remained primarily in the suprachoroidal space and choroid for a period of months

123 Infusion cannulas were placed into the suprachoroidal space and fluid-air exchange (FAE) was st

124 r positioning of the infusion cannula in the suprachoroidal space and may lead to sudden compromise o

125 The suprachoroidal space appears to be an expandible conduit

126 ollections of fluid in the outer choroid and suprachoroidal space as seen in other forms of choroidal

127 s indicated localization of India ink to the suprachoroidal space below sclera, following injection.

128 rom an infusion cannula malpositioned in the suprachoroidal space can transit through the eye to the

129 Half-lives in the suprachoroidal space for molecules of molecular weight f

130 The catheter only remains in the suprachoroidal space for the time of the drug administra

131 ing PPV to show that air can travel from the suprachoroidal space into the central circulation.

132 The suprachoroidal space is a potential space between the sc

133 ell line C918 were implanted in the superior suprachoroidal space of 11 WAG/Nij-rnu nude rats.

134 -1 spheroids were grown and implanted in the suprachoroidal space of 20, 17, and 16 WAG/RijHs-rnu nud

135 oma spheroids were implanted in the superior suprachoroidal space of 26 WAG/RijHsd-rnu nude rats.

136 of molecules and particles injected into the suprachoroidal space of the rabbit eye in vivo using a h

137 ts placed in the deep sclera adjacent to the suprachoroidal space resulted in high levels of CsA in m

138 demonstrated expansion of the tissues in the suprachoroidal space that normalized after infusion term

139 E-SC sensor (Implandata) is implanted in the suprachoroidal space to enable contactless continual IOP

140 thin the ciliary muscle and then through the suprachoroidal space to the posterior pole of the eye.

141 Injection into the suprachoroidal space using a microneedle offers a simple

142 scleral lamellar CsA implant adjacent to the suprachoroidal space was effective in achieving therapeu

143 No adverse effects of injection into the suprachoroidal space were observed.

144 Injection of pharmacotherapy into the suprachoroidal space, between the sclera and choroid, is

145 The suprachoroidal space, situated between the sclera and ch

146 By targeting the suprachoroidal space, the concentration of injected mate

147 ma, anterior chamber, subconjunctival space, suprachoroidal space, vitreous body).

148 injector can reliably deliver liquids to the suprachoroidal space-a challenging injection site that p

149 evice that connects the anterior chamber and suprachoroidal space.

150 location of the viscoelastic material in the suprachoroidal space.

151 on of ICG solution than TA suspension in the suprachoroidal space.

152 circumferentially around the eye within the suprachoroidal space.

153 le than does a similar dose delivered to the suprachoroidal space.

154 This study suggests that suprachoroidal TA could be well tolerated and efficaciou

155 Sixty-one eyes (51 patients) who underwent suprachoroidal TA injection between January 1, 2022 and

156 Fifty-two eyes underwent suprachoroidal TA injection for uveitic macular edema.

157 atients with poorly responsive ME, posterior suprachoroidal TA led to a visible suprachoroidal drug d

158 Suprachoroidal TA resulted in significant improvement in

159 For comparative efficacy study, 50muL (2mg) suprachoroidal TA versus 20mg subtenon TA were performed

160 GS combined with permanent implantation of a suprachoroidal telemetric IOP sensor (EyeMate-SC, Implan

161 To investigate the efficacy of injecting suprachoroidal triamcinolone acetonide (SCTA) plus intra

162 cinolone acetonide injectable suspension for suprachoroidal use (XIPERE(R)), administered via a micro

163 In-office suprachoroidal viscopexy (SCVEXY) is a minimally invasiv

164 Suprachoroidal viscopexy is feasible as an in-office tec